MTCR Metacrine

Metacrine to Participate in Upcoming Investor Conferences

Metacrine to Participate in Upcoming Investor Conferences

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine, will present at the following December investor conferences:

  • Piper Sandler 32nd Annual Virtual Healthcare Conference (fireside chat) being held December 1-3, 2020. Company presentations will be available for registered attendees on the Piper Sandler conference site from November 23 to December 3. Metacrine will participate in 1x1 meetings with investors during the conference on Wednesday, December 2, 2020.
  • Evercore ISI 3rd Annual HealthCONx (fireside chat) on Thursday, December 3, 2020 at 3:55 p.m. ET/12:55 p.m. PT. Metacrine will participate in 1x1 meetings with investors during the conference on Thursday, December 3, 2020.

Webcasts of the presentations will be available in the investor section of the company's website at The webcasts will be archived for 60 days following the presentations.

About Metacrine

Metacrine, Inc. (Nasdaq: MTCR) is a clinical-stage biopharmaceutical company building a differentiated pipeline of therapies to treat liver and gastrointestinal (GI) diseases. The company’s most advanced programs, MET409 and MET642, target the farnesoid X receptor (FXR), which is central to modulating liver and GI diseases. Both MET409 and MET642 are currently being investigated in clinical trials as potential new treatments for non-alcoholic steatohepatitis (NASH).

Contact:

Chelcie Lister

THRUST Strategic Communications

910.777.3049



EN
23/11/2020

Underlying

MTCRMetacrine

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Metacrine

 PRESS RELEASE
Free
MTCR METACRINE

Metacrine and Equillium Mutually Agree to Terminate Definitive Merger ...

Metacrine and Equillium Mutually Agree to Terminate Definitive Merger Agreement LA JOLLA, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger agreement. Metacrine is continuing to evaluate all strategic opportunities. Additional information regarding the termination of the definitive merger agreement is provided set forth in a Current Report on Form 8-K filed by Metacrine with the U.S. Securities and Exchange Commission today and is available at and on Metacrine...

December 23, 2022 1 EN
 PRESS RELEASE
Free
MTCR METACRINE

Metacrine Reports Third-Quarter 2022 Results

Metacrine Reports Third-Quarter 2022 Results SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases, today reported its third-quarter 2022 financial results. “We made great progress during the quarter in advancing our proposed merger with Equillium,” said Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine. “We believe that Equillium has demonstrated compelling clinical data in Lupus Nephritis and has an exciting pipeli...

November 14, 2022 1 EN
 PRESS RELEASE
Free
MTCR METACRINE

Metacrine Reports Second-Quarter 2022 Results

Metacrine Reports Second-Quarter 2022 Results SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today reported its second-quarter 2022 financial results. “We have made meaningful progress during the quarter in evaluating strategic alternatives designed to maximize stockholder value,” said Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine. Potential strategic alternatives to be explored and evaluated may includ...

August 9, 2022 1 EN
 PRESS RELEASE
Free
MTCR METACRINE

Metacrine Reports First-Quarter 2022 Results

Metacrine Reports First-Quarter 2022 Results SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today reported its first-quarter 2022 financial results and provided a business update. Metacrine announced today that it has engaged a strategic financial advisor and initiated a review of strategic alternatives with the goal of maximizing shareholder value. Potential strategic alternatives to be explored and evaluated may include a merger, sale, ...

May 12, 2022 1 EN
 PRESS RELEASE
Free
MTCR METACRINE

Metacrine Reports Fourth-Quarter 2021 Results

Metacrine Reports Fourth-Quarter 2021 Results SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today reported its fourth-quarter 2021 financial results. “We continue to devote all of our development effort to bringing expanded therapeutic options to people living with ulcerative colitis (UC),” said Preston Klassen, M.D., MHS, CEO, Metacrine. “We have generated preclinical data that supports moving our MET642 program into clinical testing ...

March 30, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch